Cosmos Health Announces Growing Momentum for C-Scrub in the United Kingdom; Now Available at Tesco, the UK’s Largest Retailer
Cosmos Health (NASDAQ:COSM) announced that its antimicrobial cleanser C-Scrub Wash Chlorhexidine 4% is now carried by Tesco, the UK’s largest retailer.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) announced that its antimicrobial cleanser C-Scrub Wash Chlorhexidine 4% is now carried by Tesco, the UK’s largest retailer. This expands C-Scrub’s UK retail footprint, increasing visibility and accessibility via Tesco’s nationwide stores and online platform, and supports future portfolio rollout in Europe.
Positive
- C-Scrub listed at Tesco, the UK market leader with nearly 30% share
- Expanded UK distribution via Tesco's nationwide store network and online platform
- Stronger market credibility and platform for future product rollouts in Europe
Negative
- None.
Details
News Market Reaction – COSM
On Feb 18, the day this news came out, COSM closed 9.53% above the previous close.
Data tracked by StockTitan Argus for the Feb 18 session.
Key Figures
- C-Scrub concentration
- 4%
- Chlorhexidine content in C-Scrub Wash Chlorhexidine 4%
- Tesco revenue
- $80 billion
- Annual revenue generated by Tesco globally
- Tesco UK share
- nearly 30%
- Tesco market share in the United Kingdom
Previous Crypto Reports
-
Showcased nutraceutical and wellness brands at World Health Expo Dubai.
-
Expanded digital assets program with $500,000 Bitcoin purchase to $2.5M total.
-
Reported customer growth, better unit economics, and robotics enabling ~$40M revenue potential.
-
Zacks initiated coverage with $4.50 valuation and strong revenue growth projections.
-
Libytec PathMuscle manufacturing deal with minimum 591,500 units over five years.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
antimicrobial medical
chlorhexidine medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHICAGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced a significant expansion of its United Kingdom (UK) retail footprint as its antimicrobial skin cleanser, C-Scrub Wash Chlorhexidine
Tesco is a leading multinational retail group operating across multiple markets and ranked among the top 20 retailers globally, generating over
Expanding distribution through this established and trusted retail platform represents a meaningful advancement in Cosmos Health’s UK growth strategy and significantly enhances C-Scrub’s visibility, accessibility, and market credibility.
C-Scrub Listed on Tesco.com
C-Scrub is a powerful antiseptic wash offering reliable skin disinfectant properties. It is designed to reduce bacteria and help prevent infection, supporting effective skin hygiene. Cosmos Health expects continued momentum for C-Scrub in the UK as it further strengthens retail partnerships and expands its distribution footprint.
Greg Siokas, CEO of Cosmos Health, stated: “C-Scrub’s entry into Tesco represents a pivotal moment for Cosmos. Building on our established online presence with Amazon, securing placement with the UK’s largest retailer significantly enhances our retail presence and strengthens our credibility in the market. Beyond the immediate growth opportunity for C-Scrub, this milestone establishes a powerful platform for the potential rollout of additional products from our portfolio over time, further solidifying our position in the UK and across broader European markets.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4f55c572-5957-454e-81d1-fb1cb2a0ee0d
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.